A Study of the Safety and Efficacy of Tobramycin for Inhalation in Young Children With Cystic Fibrosis

Completed · Phase 2

Conditions studied: Cystic Fibrosis

In brief

This study's primary goals are to test the safety and effectiveness of Tobramycin for Inhalation (TOBIr) in cystic fibrosis (CF) patients who are between 6 months and 6 years of age. This drug is an antibiotic that is inhaled into the lungs by the patient. It has already been studied and approved by the FDA for treatment of CF patients 6 years and older. Lung fluid will be examined for bacteria before and after the 28-day treatment. The amount of bacteria before and after treatment will be compared. This will indicate whether the antibiotic was effective in killing bacteria in the lungs. Once treatment begins, patients will be monitored every 2 weeks throughout the study (5 exams in 56 days). Half of the patients will receive TOBIr, half will receive a placebo (a substance that looks like TOBIr but contains no medication).

Key facts

Study ID

NCT00006280

Run by

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

People needed

98

Starts

2000-02-01

Expected to finish

2002-02-01

Last updated by the study team

2010-03-02

Who can join

Age: 1 and older, up to 5. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age at least 6 months and less than 6 years
• Diagnosis of cystic fibrosis with 2 clinical features consistent with CF and confirmed by either sweat chloride >= 60 mEq/L (by quantitative pilocarpine iontophoresis) or by genotype with 2 identifiable mutations consistent with CF.
• One throat or sputum microbiology culture positive for Pseudomonas aeruginosa (Pa) within 2 weeks to 12 months prior to screening.
• Informed consent by parent or legal guardian.

You may not qualify if…

• History of adverse reaction to anesthesia or sedation.
• History of aminoglycoside hypersensitivity.
• History of unresolved anemia (hematocrit < 30%) or thrombocytopenia (platelet count < 100,000/mm3).
• History of hemoptysis with 30 days prior to screening.
• History of abnormal renal function (serum creatinine > 1.5 times the upper limit of normal for age).
• History of clinically documented chronic hearing loss.
• Administration of any investigational drug within 30 days prior to screening.

Where it is running

• Stanford University/Lucille Packard Children's Health Services at Stanford — Palo Alto, California, United States
• The Children's Hospital — Denver, Colorado, United States
• Johns Hopkins Hospital — Baltimore, Maryland, United States
• Children's Hospital — Boston, Massachusetts, United States
• University of North Carolina - Chapel Hill — Chapel Hill, North Carolina, United States
• Children's Hospital Medical Center — Cincinnati, Ohio, United States
• Rainbow Babies and Children's Hospital — Cleveland, Ohio, United States
• Baylor College of Medicine — Houston, Texas, United States
• Children's Hospital and Regional Medical Center — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.